1
|
Revilla G, Pons MDP, Baila-Rueda L, García-León A, Santos D, Cenarro A, Magalhaes M, Blanco RM, Moral A, Ignacio Pérez J, Sabé G, González C, Fuste V, Lerma E, Faria MDS, de Leiva A, Corcoy R, Carles Escolà-Gil J, Mato E. Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness. Sci Rep 2019; 9:10260. [PMID: 31311983 PMCID: PMC6635382 DOI: 10.1038/s41598-019-46727-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 07/04/2019] [Indexed: 01/16/2023] Open
Abstract
Cholesterol mediates its proliferative and metastatic effects via the metabolite 27-hydroxycholesterol (27-HC), at least in breast and endometrial cancer. We determined the serum lipoprotein profile, intratumoral cholesterol and 27-HC levels in a cohort of patients with well-differentiated papillary thyroid carcinoma (PTC; low/intermediate and high risk), advanced thyroid cancers (poorly differentiated, PDTC and anaplastic thyroid carcinoma, ATC) and benign thyroid tumors, as well as the expression of genes involved in cholesterol metabolism. We investigated the gene expression profile, cellular proliferation, and migration in Nthy-ori 3.1 and CAL-62 cell lines loaded with human low-density lipoprotein (LDL). Patients with more aggressive tumors (high-risk PTC and PDTC/ATC) showed a decrease in blood LDL cholesterol and apolipoprotein B. These changes were associated with an increase in the expression of the thyroid’s LDL receptor, whereas 3-hydroxy-3-methylglutaryl-CoA reductase and 25-hydroxycholesterol 7-alpha-hydroxylase were downregulated, with an intratumoral increase of the 27-HC metabolite. Furthermore, LDL promoted proliferation in both the Nthy-ori 3.1 and CAL-62 thyroid cellular models, but only in ATC cells was its cellular migration increased significantly. We conclude that cholesterol and intratumoral accumulation of 27-HC promote the aggressive behavior process of PTC. Targeting cholesterol metabolism could be a new therapeutic strategy in thyroid tumors with poor prognosis.
Collapse
Affiliation(s)
- Giovanna Revilla
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Departament de Bioquímica, Biologia Molecular i Biomedicina, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Monica de Pablo Pons
- Department of Endocrinology-EDUAB-HSP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Lucía Baila-Rueda
- Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.,CIBER de Enfermedades Cardiovasculares, CIBERCV, Madrid, Spain
| | - Annabel García-León
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - David Santos
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Madrid, Spain
| | - Ana Cenarro
- CIBER de Enfermedades Cardiovasculares, CIBERCV, Madrid, Spain
| | - Marcelo Magalhaes
- Service of Endocrinology, Clinical Research Center (CEPEC), Hospital of the Federal University of Maranhão (HUUFMA), São Luís, Maranhão, Brazil
| | - R M Blanco
- CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain
| | - Antonio Moral
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Department of General Surgery-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Medicine Department, Autonomous University of Barcelona (UAB), Barcelona, Spain
| | - José Ignacio Pérez
- Department of General Surgery-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Gerard Sabé
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Cintia González
- Department of Endocrinology-EDUAB-HSP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain
| | - Victoria Fuste
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Department of Anatomic Pathology-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - Enrique Lerma
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Department of Anatomic Pathology-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - Manuel Dos Santos Faria
- Service of Endocrinology, Clinical Research Center (CEPEC), Hospital of the Federal University of Maranhão (HUUFMA), São Luís, Maranhão, Brazil
| | - Alberto de Leiva
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain
| | - Rosa Corcoy
- Department of Endocrinology-EDUAB-HSP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain.,Medicine Department, Autonomous University of Barcelona (UAB), Barcelona, Spain
| | - Joan Carles Escolà-Gil
- Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. .,Departament de Bioquímica, Biologia Molecular i Biomedicina, Universitat Autònoma de Barcelona, Barcelona, Spain. .,CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Madrid, Spain.
| | - Eugenia Mato
- Department of Endocrinology-EDUAB-HSP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. .,CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Madrid, Spain.
| |
Collapse
|